Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2172608 | 1.00 | — | — | |
| SCHEMBL5237712 | 1.00 | — | — | |
| Hydrogen Sulfide SCHEMBL27357507 | 0.87 | — | — | |
| SCHEMBL7641097 | 0.87 | — | — | |
| SCHEMBL27510407 | 0.87 | — | — | |
| SCHEMBL8599079 | 0.87 | — | — | |
| Water SCHEMBL27269067 | 0.87 | — | — | |
| SCHEMBL208 | 0.82 | — | — | |
| SCHEMBL3408563 | 0.82 | — | — | |
| SCHEMBL31122202 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12570666-B2 | Furoindazole derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2026-03-10 | — | — | US | disclosed |
| EP-4077334-B1 | FUROINDAZOLE DERIVATIVES | BAYER AG (DE) | 2025-03-12 | — | — | EP | disclosed |
| US-20230112499-A1 | FUROINDAZOLE DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2023-04-13 | — | — | US | disclosed |
| EP-4077334-A1 | FUROINDAZOLE DERIVATIVES | Bayer Aktiengesellschaft (DE) | 2022-10-26 | — | — | EP | disclosed |
| WO-2021122415-A9 | FUROINDAZOLE DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2022-06-30 | — | — | WO | disclosed |
| US-20220089540-A1 | COMPOSITIONS AND METHODS FOR IMMUNE MODULATION AND TREATMENT OF CANCER | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY | 2022-03-24 | — | — | US | disclosed |
| EP-3911309-A1 | COMPOSITIONS AND METHODS FOR IMMUNE MODULATION AND TREATMENT OF CANCER | Board Of Trustees Of Michigan State University (US) | 2021-11-24 | — | — | EP | disclosed |
| WO-2021122415-A1 | FUROINDAZOLE DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2021-06-24 | — | — | WO | disclosed |
| WO-2021033980-A1 | NOVEL COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE USING SAME | 주식회사 엘지화학 | 2021-02-25 | — | — | WO | disclosed |
| WO-2020150668-A1 | COMPOSITIONS AND METHODS FOR IMMUNE MODULATION AND TREATMENT OF CANCER | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) | 2020-07-23 | — | — | WO | disclosed |
| EP-2262795-A1 | MUSCARINIC RECEPTOR AGONISTS, COMPOSITIONS, METHODS OF TREATMENT THEREOF, AND PROCESSES FOR PREPARATION THEREOF | AstraZeneca AB (SE) | 2010-12-22 | — | — | EP | disclosed |
| WO-2009110844-A1 | MUSCARINIC RECEPTOR AGONISTS, COMPOSITIONS, METHODS OF TREATMENT THEREOF, AND PROCESSES FOR PREPARATION THEREOF | ASTRAZENECA AB (SE) | 2009-09-11 | — | — | WO | disclosed |
| US-20090221642-A1 | MUSCARINIC RECEPTOR AGONISTS, COMPOSITIONS, METHODS OF TREATMENT THEREOF, AND PROCESSES FOR PREPARATION THEREOF-176 | ASTRAZENECA AB (SE) | 2009-09-03 | — | — | US | disclosed |
| US-7053099-B1 | 3,4-dihydro-(1H)quinazolin-2-one compounds as CSBP/p38 kinase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2006-05-30 | — | — | US | disclosed |
| EP-1235814-B1 | 3,4-DIHYDRO-(1H)QUINAZOLIN-2-ONE COMPOUNDS AS CSBP/p38 KINASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2004-11-03 | — | — | EP | disclosed |
| US-4195042-A | Rhodium hydroformylation catalyst | PHILLIPS PETROLEUM COMPANY (US) | 1980-03-25 | — | — | US | disclosed |
| US-3956177-A | Rhodium hydroformylation catalyst | PHILLIPS PETROLEUM COMPANY (US) | 1976-05-11 | — | — | US | disclosed |